January 01, 2024

LIVESTREAM Q + A

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Contact Lens Spectrum

July 01, 2024

ARVO 2024: 96-Week Results of High-Dose Aflibercept with Extended Dosing Intervals from PULSAR

BCVA gains and CRT reductions at week 96 were consistent across all subgroups.

Conexiant

October 01, 2023

AAO 2023 TO MEET IN SAN FRANCISCO

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Ophthalmology Management

July 01, 2024

ARVO 2024: New Algorithm Identifies 3 Times More UME Patients than ICD-10 Codes Alone

The algorithm could support future real-world evidence studies for patients with active uveitic macular edema

Conexiant

January 01, 2023

TrendSpotting

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Eyecare Business

December 01, 2023

THE GLOBAL SPECIALTY LENS SYMPOSIUM GUIDE

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Contact Lens Spectrum

July 01, 2024

Clinical Results from ARCHER Trial at ARVO 2024

ANX007 potentially significantly alters the progression of retinal diseases by protecting critical aspects of retinal structure and function.

Conexiant

July 18, 2024

ASRS 2024: Data from Phase 1 of HELIOS for Sustained-Release Axitinib Implant

"Despite research in the Protocol W study that found anti-VEGF treatment of NPDR to reduce vision-threatening complications, less than 1% of patients are treated."

Conexiant

July 01, 2024

Vision Outcomes from Assessment of Time to First Anti-VEGF Injection Presented at ARVO 2024

Each additional day from symptom onset to first anti-VEGF injection corresponded to visual outcomes at 1-year follow up.

Conexiant